JP2019194209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019194209A5 JP2019194209A5 JP2019111139A JP2019111139A JP2019194209A5 JP 2019194209 A5 JP2019194209 A5 JP 2019194209A5 JP 2019111139 A JP2019111139 A JP 2019111139A JP 2019111139 A JP2019111139 A JP 2019111139A JP 2019194209 A5 JP2019194209 A5 JP 2019194209A5
- Authority
- JP
- Japan
- Prior art keywords
- psma
- composition
- abgenix
- ligand
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076905A JP2023135666A (ja) | 2013-10-18 | 2023-05-08 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893145P | 2013-10-18 | 2013-10-18 | |
| US61/893,145 | 2013-10-18 | ||
| JP2013235506A JP6908964B2 (ja) | 2013-10-18 | 2013-11-13 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013235506A Division JP6908964B2 (ja) | 2013-10-18 | 2013-11-13 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076905A Division JP2023135666A (ja) | 2013-10-18 | 2023-05-08 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019194209A JP2019194209A (ja) | 2019-11-07 |
| JP2019194209A5 true JP2019194209A5 (https=) | 2020-01-16 |
| JP7716836B2 JP7716836B2 (ja) | 2025-08-01 |
Family
ID=53009949
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013235506A Active JP6908964B2 (ja) | 2013-10-18 | 2013-11-13 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| JP2019111139A Active JP7716836B2 (ja) | 2013-10-18 | 2019-06-14 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| JP2023076905A Pending JP2023135666A (ja) | 2013-10-18 | 2023-05-08 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013235506A Active JP6908964B2 (ja) | 2013-10-18 | 2013-11-13 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076905A Pending JP2023135666A (ja) | 2013-10-18 | 2023-05-08 | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP3827844A1 (https=) |
| JP (3) | JP6908964B2 (https=) |
| AU (3) | AU2014337391B2 (https=) |
| CA (2) | CA2927735C (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| WO2018204477A1 (en) * | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| WO2019088176A1 (ja) * | 2017-10-31 | 2019-05-09 | 国立大学法人神戸大学 | 抗体薬物複合体効果増強剤 |
| EP4344747A3 (en) * | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
| US20200297877A1 (en) | 2017-12-13 | 2020-09-24 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| WO2020077259A1 (en) * | 2018-10-11 | 2020-04-16 | Progenics Pharmaceuticals, Inc | Combination therapy for treating metastatic prostate cancer |
| CN119792549A (zh) * | 2021-04-23 | 2025-04-11 | 天津全和诚生物技术有限公司 | 缀合物及其制备方法和用途 |
| WO2025125469A1 (en) * | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
| CN117778322B (zh) * | 2023-12-17 | 2025-02-07 | 苏州拓维生物技术有限公司 | 一种对恩杂鲁胺耐药的细胞系的筛选方法及其应用 |
| WO2025216238A1 (ja) * | 2024-04-09 | 2025-10-16 | 国立大学法人広島大学 | 薬物コンジュゲート又はその塩 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| US5756825A (en) | 1992-09-08 | 1998-05-26 | Safavy; Ahmad | Hydroxamic acid-based bifunctional chelating compounds |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5994292A (en) | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| JP5355839B2 (ja) | 2001-10-23 | 2013-11-27 | ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． | Ｐｓｍａ抗体およびタンパク質マルチマー |
| DK1912677T3 (da) | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| EP2097111B1 (en) | 2006-11-08 | 2015-07-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| EP2326350B1 (en) * | 2008-09-08 | 2013-09-04 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| AU2010260195B2 (en) | 2009-06-15 | 2014-11-20 | Molecular Insight Pharmaceuticals, Inc. | Process for production of heterodimers of glutamic acid |
| US20140099257A1 (en) * | 2012-10-05 | 2014-04-10 | Cornell University | Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability |
-
2013
- 2013-11-13 JP JP2013235506A patent/JP6908964B2/ja active Active
-
2014
- 2014-05-14 CA CA2927735A patent/CA2927735C/en active Active
- 2014-05-14 EP EP20199101.5A patent/EP3827844A1/en active Pending
- 2014-05-14 CA CA3181096A patent/CA3181096A1/en active Pending
- 2014-05-14 AU AU2014337391A patent/AU2014337391B2/en active Active
- 2014-05-14 EP EP14734570.6A patent/EP3057614B1/en active Active
-
2019
- 2019-06-14 JP JP2019111139A patent/JP7716836B2/ja active Active
-
2020
- 2020-05-15 AU AU2020203191A patent/AU2020203191B2/en active Active
-
2023
- 2023-02-17 AU AU2023200926A patent/AU2023200926A1/en not_active Abandoned
- 2023-05-08 JP JP2023076905A patent/JP2023135666A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019194209A5 (https=) | ||
| JP2015078168A5 (https=) | ||
| JP7354079B2 (ja) | 尿路の新生物の治療における使用のための多重特異性抗体 | |
| Hamann et al. | An anti-MUC1 antibody− calicheamicin conjugate for treatment of solid tumors. choice of linker and overcoming drug resistance | |
| JP2009197002A5 (https=) | ||
| JP2010513303A5 (https=) | ||
| JP6426607B2 (ja) | １５８ｐ１ｄ７タンパク質に結合する抗体薬物結合体（ａｄｃ） | |
| JP2011524421A5 (https=) | ||
| JP2009506790A5 (https=) | ||
| JP2017500028A (ja) | 新規の抗ｄｐｅｐ３抗体および使用方法 | |
| Cheng et al. | Efficient clearance of poly (ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy | |
| CN102448486A (zh) | 结合于24p4c12蛋白的抗体药物偶联物(adc) | |
| JP2016536020A (ja) | 新規の抗クローディン抗体および使用方法 | |
| JP2013227339A5 (https=) | ||
| EP2079482B1 (fr) | Utilisation d'un anticorps anti-cd151 pour le traitement de cancer primaire | |
| JP2022512750A5 (https=) | ||
| JP2016532688A (ja) | Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ） | |
| JP2005505256A5 (https=) | ||
| CN107921018A (zh) | 药物组合及其应用 | |
| RU2016130349A (ru) | Способы применения антител против steap1 и иммуноконъюгатов | |
| JP2019511199A (ja) | 新規の抗ｕｐｋ１ｂ抗体及び使用方法 | |
| JP2011505371A5 (https=) | ||
| JP2019533677A5 (https=) | ||
| EP1230270A1 (en) | Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents | |
| Yu et al. | Advances in antibody-drug conjugates in the treatment of HER2-positive breast cancer |